30
Participants
Start Date
October 31, 2007
Study Completion Date
November 30, 2012
Sunitinib (SU011248)
SU011248 (study medication) will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2 week rest period to form a complete cycle of 6 weeks. Study medication will be orally self administered once daily without regard to meals beginning on Day 1 of the study. Cycles will be repeated in the absence of unacceptable toxicity or disease progression
Tom Baker Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
Vancouver Cancer Centre, Vancouver
London Health Sciences Centre, London
Collaborators (1)
Pfizer
INDUSTRY
Alberta Health services
OTHER